Defining long-term outcomes with living donor liver transplantation in North America.

Ann Surg

*Department of Surgery, University of Pennsylvania, Philadelphia, PA †Department of Biostatistics, University of Michigan, Ann Arbor, MI ‡Arbor Research Collaborative for Health, Ann Arbor, MI §Northwestern University Comprehensive Transplant Center, Chicago, IL ¶Center for Liver Disease and Transplantation, Columbia University, New York, NY ∥Duke University Health System, Durham, NC **Department of Medicine, University of Colorado, Aurora, CO ††Division of Transplantation, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA ‡‡Department of Surgery, University of California San Francisco, San Francisco, CA §§Department of General Surgery, Toronto Hospital, General Division, Toronto, Ontario, Canada ¶¶Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA ∥∥Department of Surgery, University of Colorado, Denver, CO ***Department of Surgery, University of Michigan, Ann Arbor, MI; and †††Department of Transplantation, Lahey Clinic Medical Center, Tufts University School of Medicine, Boston, MA.

Published: September 2015

Objectives: To compare long-term survival of living donor liver transplant (LDLT) at experienced transplant centers with outcomes of deceased donor liver transplant and identify key variables impacting patient and graft survival.

Background: The Adult-to-Adult Living Donor Liver Transplantation Cohort Study is a prospective multicenter National Institutes of Health study comparing outcomes of LDLT and deceased donor liver transplant and associated risks.

Methods: Mortality and graft failure for 1427 liver recipients (963 LDLT) enrolled in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study who received transplant between January 1, 1998, and January 31, 2014, at 12 North American centers with median follow-up 6.7 years were analyzed using Kaplan-Meier and multivariable Cox models.

Results: Survival probability at 10 years was 70% for LDLT and 64% for deceased donor liver transplant. Unadjusted survival was higher with LDLT (hazard ratio = 0.76, P = 0.02) but attenuated after adjustment (hazard ratio = 0.98, P = 0.90) as LDLT recipients had lower mean model for end-stage liver disease (15.5 vs 20.4) and fewer received transplant from intensive care unit, were inpatient, on dialysis, were ventilated, or with ascites. Posttransplant intensive care unit days were less for LDLT recipients. For all recipients, female sex and primary sclerosing cholangitis were associated with improved survival, whereas dialysis and older recipient/donor age were associated with worse survival. Higher model for end-stage liver disease score was associated with increased graft failure. Era of transplantation and type of donated lobe did not impact survival in LDLT.

Conclusions: LDLT provides significant long-term transplant benefit, resulting in transplantation at a lower model for end-stage liver disease score, decreased death on waitlist, and excellent posttransplant outcomes. Recipient diagnosis, disease severity, renal failure, and ages of recipient and donor should be considered in decision making regarding timing of transplant and donor options.Clinical Trials ID: NCT00096733.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545521PMC
http://dx.doi.org/10.1097/SLA.0000000000001383DOI Listing

Publication Analysis

Top Keywords

donor liver
28
living donor
16
liver transplant
16
liver transplantation
12
deceased donor
12
model end-stage
12
end-stage liver
12
liver disease
12
liver
11
donor
9

Similar Publications

Background: Mycobacterium avium complex (MAC) is a common pathogen causing non-tuberculous mycobacterial infections, primarily affecting the lungs. Disseminated MAC disease occurs mainly in immunocompromised individuals, such as those with acquired immunodeficiency syndrome, hematological malignancies, or those positive for anti-interferon-γ antibodies. However, its occurrence in solid organ transplant recipients is uncommon.

View Article and Find Full Text PDF

The risk of donor-acquired allergy in solid organ transplant recipients: a systematic review.

Ann Allergy Asthma Immunol

January 2025

Center for Drug Safety and Immunology, Vanderbilt University Medical Centre, Nashville, Tennessee, USA; Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, Australia.

Background: Donor acquired allergy (DAA) occurs when donors transfer their allergies to recipients through solid organ transplant (SOT). However, the risk of DAA in recipients of organs from allergic donors has not been systematically characterized.

Objective: We sought to synthesize the available evidence on the risk of DAA in SOT recipients.

View Article and Find Full Text PDF

The Potential of Neonatal Organ Donation in Central Sweden.

Cell Transplant

January 2025

Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.

Pediatric organ transplant recipients have a higher risk for wait list mortality due to the scarcity of size matched organs. Neonatal organ donation could potentially ameliorate the discrepancy but is currently not implemented in Sweden. This study aims to evaluate the potential of neonatal organ donation in central Sweden using a standardized protocol with organ specific criteria.

View Article and Find Full Text PDF

Establishment of iPSC-Derived MSCs Expressing hsa-miR-4662a-5p for Enhanced Immune Modulation in Graft-Versus-Host Disease (GVHD).

Int J Mol Sci

January 2025

Catholic High-Performance Cell Therapy Center & Department of Medical Life Science, College of Medicine, The Catholic University of Korea, Seocho-gu, Seoul 06591, Republic of Korea.

The immune-modulatory effects of mesenchymal stromal cells (MSCs) are widely used to treat inflammatory disorders, with indoleamine 2,4-dioxygenase-1 (IDO-1) playing a pivotal role in suppressing stimulated T-cell proliferation. Taking that three-dimensional (3D) cultures enhance MSCs' anti-inflammatory properties compared with two-dimensional (2D) cultures, the differentially expressed miRNAs were examined. Thus, we identified hsa-miR-4662a-5p (miR-4662a) as a key inducer of IDO-1 via its suppression of bridging integrator-1 (BIN-1), a negative regulator of the IDO-1 gene.

View Article and Find Full Text PDF

Liver transplantation is the only curative option for end-stage liver disease and is necessary for an increasing number of patients with advanced primary or secondary liver cancer. Many patient groups can benefit from this treatment, however the shortage of liver grafts remains an unsolved problem. Liver bioengineering offers a promising method for expanding the donor pool through the production of acellular scaffolds that can be seeded with recipient cells.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!